

PTO/SB/08 (2/92)
Sheet 1 of 1

Form PTO-1449		Attorney's Docket No. 39750-0065A		Application Serial No. 09/272,835			
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Frederic J. de SAUVAGE, et al.					
(use several sheets if necessary)		Filing Date: March 19, 1999		Group Art Unit: 1647			
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class s	Subclass ss	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class s	Subclass ss	Translation YES NO
OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
P	1	Andres et al., <i>Development</i> 128(10):3685-3695 (2001) Multiple effects of artemin on sympathetic neurone generation, survival and growth					
	2	Baloh et al., <i>Neuron</i> 21: 1291-1302 (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex					
	3	Esteve, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," <i>The Oncologist</i> 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16).					
	4	Negro et al., <i>Recent Prog Horm Res.</i> 59:1-12 (2004) Essential roles of Her2/erbB2 in cardiac development and function					
	5	Rosická et al., <i>Physiological Research</i> 51:435-441 (2002) Ghrelin - a New Endogenous Growth Hormone Secretagogue					
	6	Smith et al., <i>Best Pract Res Clin endocrinol Metab.</i> 18(3):333-347 (2004) Growth hormone secretagogues: prospects and potential pitfalls					
	7	Thilenius et al., <i>Eur. J. Immunol.</i> 27(5):1108-1114 (1997) Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants					
EXAMINER: Payer			DATE CONSIDERED: 3/24/05				
EXAMINER: Initial If citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).							